Absci Corporation Common Stock
ABSIAbsci Corporation is a biotechnology company specializing in artificial intelligence-driven drug discovery and development. It leverages its proprietary platform to streamline the creation of biologics and identify new therapeutic candidates efficiently, aiming to accelerate the journey from discovery to clinical trials.
Company News
The AI drug discovery field is shifting focus from building the most powerful models to establishing trustworthy, connected biological data foundations. MindWalk Holdings (HYFT) has positioned itself as a leader in this 'context layer' approach with its ReefIQ and LensAI platforms, reporting 52% YoY revenue growth and its first recurring platform...
AMD disclosed a $6.5 million stake in Marvell Technology through its latest 13F filing, with the position showing an estimated unrealized gain of approximately $4.3 million as Marvell shares have risen about 66% from AMD's implied entry price. The investment reflects AMD's exposure to AI infrastructure and data center semiconductor opportunities....
Absci Corporation granted 276,200 non-statutory stock options to a newly-hired non-executive employee on May 1, 2026, as an inducement for employment. The options have an exercise price of $4.92 per share with a 10-year term and vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over ...
Absci Corporation announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer to lead clinical development of its AI-designed therapeutics pipeline. Dr. Somaratne joins from Vertex Pharmaceuticals with extensive experience in clinical development. Chief Innovation Officer Andreas Busch will retire on March 31, 2026 and ...
Absci, a clinical-stage biotech company using generative AI for drug discovery, will report its Q3 2025 financial and operating results on November 12, 2025, via a webcast conference call.
